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ABSTRACT
Background: Familial (FHM) and sporadic (SHM) hemiplegic migraine are severe subtypes of mi-
graine associated with transient hemiparesis. For FHM, three genes have been identified encod-
ing subunits of a calcium channel (CACNA1A), a sodium–potassium pump (ATP1A2), and a sodium
channel (SCN1A). Their role in SHM is unknown. Establishing a genetic basis for SHMmay further
the understanding of its pathophysiology and relationship with common types of migraine. It will
also facilitate the often difficult differential diagnosis from other causes of transient hemiparesis.
Methods: We systematically scanned 39 well-characterized patients with SHM without associ-
ated neurologic features for mutations in the three FHM genes. Functional assays were per-
formed for all new sequence variants.
Results: Sequence variants were identified in seven SHM patients: one CACNA1A mutation, five
ATP1A2 mutations, and one SCN1A polymorphism. All six mutations caused functional changes
in cellular assays. One SHM patient later changed to FHM because another family member devel-
oped FHM attacks.
Conclusion:We show that FHM genes are involved in at least a proportion of SHM patients with-
out associated neurologic symptoms. Screening of ATP1A2 offers the highest likelihood of suc-
cess. Because FHM gene mutations were also found in family members with “nonhemiplegic”
typical migraine with and without aura, our findings reinforce the hypothesis that FHM, SHM, and
“normal” migraine are part of a disease spectrum with shared pathogenetic mechanisms.
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GLOSSARY
ATPase  adenosine triphosphatase; BAM  basilar artery migraine; Ctrl  control; cDNA  complementary DNA; Fam 
family; FHM familial hemiplegic migraine;HM hemiplegic migraine; IHS International Headache Society;MAmigraine
with aura; MOmigraine without aura; SHM sporadic hemiplegic migraine; WTwild type.
Hemiplegic migraine is a rare, often severe subtype of migraine with aura in which at-
tacks are associated with hemiparesis.1 Otherwise, the aura and headache symptoms are
identical to those of common types of migraine.2 Hemiplegic migraine may run in fami-
lies (familial hemiplegic migraine [FHM]) or may be sporadic (SHM).1 Clinically, FHM
and SHM attacks are indistinguishable, and the majority of patients also have common
attacks of migraine with or without aura, not associated with hemiparesis.3
Thus far, three genes for FHM have been identified. The CACNA1A gene (FHM1)4
encoding the pore-forming subunit Cav2.1 of neuronal P/Q-type calcium channels, the
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ATP1A2 gene (FHM2)5 encoding the 2
subunit of sodium–potassium pumps, and
the SCN1A gene (FHM3)6 encoding the 1
subunit of neuronal sodium channels.
Although clinically indistinguishable,3 it is
unknown whether and to what extent SHM
and FHM are pathophysiologically related
and whether and to what extent FHM genes
are also involved in SHM. Previous studies
identified mutations in the CACNA1A gene
in SHM patients.7-11 Most of these patients
showed cerebellar signs, suggesting an in-
volvement of the CACNA1A gene in SHM
with associated cerebellar and other neuro-
logic signs or symptoms, such as cerebral
edema and coma afterminor head trauma. In
contrast, the role of the FHMgenes in “pure”
SHM without associated neurologic symp-
toms is less clear. One CACNA1Amutation
(R583Q)8 and one ATP1A2 mutation
(R383H)12 were reported in such patients.
Investigating the involvement of FHM
genes in sporadic patients with hemiplegic
migraine is important because it may further
the insight into the pathophysiology of SHM
and the relationship with other types of mi-
graine. Moreover, understanding and estab-
lishing the genetic basis of SHM may help
clinicians in diagnostic and therapeutic deci-
sion making. Many patients are initially mis-
diagnosed and mistreated. We therefore set
out to search systematically for mutations in
the known FHM genes in a large set of 39
clinically well-characterized patients with
“pure” SHM, who had no interictal neuro-
logic symptoms.
METHODS Patients. Sporadic hemiplegic migraine was
diagnosed according to the criteria of the International
Headache Society (IHS).1 Patients with interictal neurologic
symptoms, in particular ataxia, were excluded because these
patients have a high a priori probability of carrying a
CACNA1A mutation.7-11 All available family members were
directly interviewed, and their headache was diagnosed ac-
cording to the IHS criteria. In addition to newly recruited
SHM patients, we included 25 of the 27 patients from our
previous study in which only the FHM1 CACNA1A gene
was investigated.8 Two patients from that study were ex-
cluded because of associated symptoms; one had ataxia and
carried the T666M mutation, the other patient had child-
hood epilepsy and did not carry a CACNA1Amutation. Ap-
proval was obtained by local ethical committees in
accordance with national legislation; all patients gave in-
formed consent.
Mutation scanning. Genomic DNA was isolated from pe-
ripheral leukocytes using a standard salting out extraction
method. The CACNA1A, ATP1A2, and SCN1A genes were
screened for mutations by sequencing.6,8,13 In brief, all exons
and flanking intronic regions were amplified by PCR, using
genomic DNA as a template. Direct sequencing was per-
formed with Cycle Sequencing (Prism Big Dye Terminators
Cycle Sequencing kit, Applied Biosystems, Foster City, CA)
using the dideoxy termination method and an ABI3700 auto-
mated sequencer (Applied Biosystems). For each exonic vari-
ant identified, 150 healthy controls were screened, by
restriction enzyme analysis or direct sequencing. Detailed in-
formation is available from the authors on request.
Functional analysis. Functional analysis of mutations in
the Cav2.1-1 calcium channel subunit was not performed
because the single CACNA1A mutation found in this study
was thoroughly investigated before.14 Functional analysis of
ATP1A2 variants was performed by survival assays. Human
Na,K–adenosine triphosphatase (ATPase) 2-subunit com-
plementary DNA (cDNA) was subcloned into a modified
pCDNA3.1 vector.15 To distinguish endogenous Na,K-
ATPase activity from that of transfected Na,K-ATPase, we
used a cDNA construct encoding ouabain-resistant wild-
type (ATP1A2-WT).15,16 Mutations E120A, E492K, P786L,
R834X, and R908Qwere introduced in the ouabain-resistant
wild-type 2-subunit construct by site-directed mutagenesis
(Quikchange, Stratagene, La Jolla, CA). HeLa cells (5 105)
were transfected with plasmid DNA of either ATP1A2-WT
or ATP1A2-mutant (ATP1A2-E120A, ATP1A2-E492K,
ATP1A2-P789L, ATP1A2-R834X, ATP1A2-R908Q) using
Lipofectamine 2000 Transfection Reagent (Invitrogen,
Carlsbad, CA). Two days after transfection, two-thirds of
the cells were harvested for immunoblotting, and the 2-
subunit protein was detected using the specific polyclonal
antibody HERED.15,16 The remaining one-third of the cells
was seeded on 10-cm petri dishes, and subsequently 1 M
ouabain was added to the culture medium. After 5 days of
ouabain challenge, colonies were stained with 1%methylene
blue in 70% methanol, scanned, and analyzed with Image
Pro Plus (MediaCybernetics, Silver Spring, MD). Each trans-
fection was performed 7 to 15 times. In case of partial sur-
vival, statistical significance was tested using Student t test
(p 0.05).
For functional analysis of the SCN1A variant, we used
the closely related SCN5A cDNA, because of the known sta-
bility problems of recombinant bacteria with SCN1A
cDNA.6,17 R1914G, which corresponds to SCN1A R1928G,
was introduced by site-directed mutagenesis into full-length
human SCN5A cDNA subcloned in pCDNA3.1
(QuikChange XL Kit, Stratagene). SCN5A-R1914G and
SCN5A-WT cDNAs were transfected into human tsA201
cells and were each coexpressed with accessory human so-
dium channel subunit 1.6 Macroscopic sodium currents
were recorded using the whole-cell configuration of the
patch clamp technique.6 Steady state activation, steady state
inactivation, time constants of inactivation (e.g., time con-
stants fh and sh), and recovery from inactivation (e.g., fast
and slow time constants) were measured using protocols, as
described before.6
RESULTS Patients. Thirty-nine patients with
“pure” SHM were included; 37 originated from
Western Europe (mostly The Netherlands or Ger-
Neurology 69 December 4, 2007 2171
many) and 2 came from the United States (table
1). As expected,3,18 some of the patients exhibited
basilar-type migraine symptoms during the at-
tacks, but they were all free of interictal signs or
symptoms. Age at onset of hemiplegic attacks
ranged from 4 to 42 years. The number of attacks
varied from 2 per lifetime to more than 200 per
year. Likewise, duration of hemiparesis was vari-
able, from several minutes to 1 week. Four pa-
tients reported loss of consciousness during
Table 1 Clinical and genetic characteristics of SHM patients
Patient
Mutation in
HM gene
Age at
onset, y
Frequency
of attacks,
per y
Total
duration
of attack
Duration of
paresis
BAM
symptoms
Unconsciousness
during attacks
Attacks
triggered
by minor
head trauma
MO or MA in
first-degree
family members
1 No 27 3 1–2 d Minutes No No No MO
2 No 20 4 4 h–2 d 0.5–2 h No No No MA
3 No 12 ? Days Hours No No No MA
4 No 18 24 15–60 min 15 min No No No MO
5 No 20 0–3 8 h 1 h No No No No
6 ATP1A2- R834X 10 1 4 d 2 d No No Yes MO
7 No 22 12 12 h 0.5–2 h No No No MO and MA
8 No 9 12–30 1–3 d 1 h–1 d No No No MA
9 No 25 24 Hours–3 d 0.5–1 h Yes No No MO
10 No 12 4–36 1–2 d 5–10 min No Yes No No
11 No 19 2 in lifetime 20 min–1 h 20 min No No No MA
12 ATP1A2-E120A 13 12–250 1 d 1 h No No No No
13 No 25 48 10–24 h ? ? No No MO and MA
14 No 13 2–6 Few hours 0.5 h No No No MO and MA
15 No 29 2–100 Minutes–hours Minutes–hours Yes Yes Yes No
16 No 4 24 1 d Few hours Yes No No MA
17 No 10 Once 1 d 1 h No No No MO and MA
18 No 20 0–2 1 wk–1 mo 1 wk–1 mo ? No No MO
19 ATP1A2-P786L 5 0.5 3 wk 6 d No No No No
20 No 16 12 1 d 1 h No No No MO and MA
21 No 13 Once Few days Few days No No No MO and MA
22 No 13 2–52 1 d 0.5–1 h No No No No
23 ATP1A2-E492K 19 2 ? ? No No No MA
24 No 32 2–12 Days Hours–days No No No No
25 CACNA1A-R583Q 13 2 1 d 0.5 h No No No MA
26 No 34 8 0.5? Hours? No No No No
27 No 37 36–48 3–48 h? Hours–48 h No No No MO or MA?
28 SCN1A-R1928G 38 2 in lifetime Few hours 1.5 h No Yes No MO and MA
29 No 42 2 in lifetime 3–4 hours 0.5 h No No No Migraine unspecified
30 No 11 30 in lifetime Hours 1 h No No No MA and migraine
unspecified
31 No 17 24 Up to 4 h 3–4 h No No No MA in grandmother
32 No 22 up to 50 Hours Hours No No No No
33 No 15 4 to 10 1 h 15–30 min No No No Migraine unspecified
34 ATP1A2-R908Q 5 2 to 5 2 h 30–90 min Yes No No No
35 No 27 5 in lifetime Up to 7 h Up to 7 h No No No MO and MA
36 No 16 4 1.5–3 h 1–3 h No No No No
37 No 4 4 Hours 24–72 h No No No No
38 No 8 2–12 Hours 15–60 min No No No No
39 No 35 5 Few hours 15 min–3 h No Yes No MA
SHM sporadic hemiplegic migraine; HM hemiplegic migraine; BAM basilar artery migraine; MOmigraine without aura; MAmigraine with aura.
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attacks; 2 patients reported triggering of attacks
by minor head trauma. In 1 patient, the initial di-
agnosis was later changed to FHM, when a family
member developed hemiplegic migraine attacks.
Notwithstanding, this patient was kept in the
SHM group because he fulfilled the inclusion cri-
teria of SHM at the time of clinical presentation.
In approximately 70% of the families of our 39
SHM patients, attacks of common nonhemiplegic
migraine with aura (one-third), without aura
(one-third), or both (one-third) were present in
one or more first-degree relatives.
Genetic and functional findings. Sequencing of all
exons and flanking intronic sequences in the 39
index cases revealed seven different sequence
variants which were present in seven probands
(table 2 and figure 1): one in CACNA1A, five in
ATP1A2, and one the SCN1A gene. None of the
sequence variants was present in 150 healthy con-
trols (data not shown).
CACNA1A. The single variant in the CACNA1A
gene (R583Q) has been reported as part of our
earlier study.8 R583Q was present in the index
case and his unaffected mother, who had mi-
graine with aura but no hemiplegic attacks indi-
cating incomplete penetrance. R583Q has
previously been identified in families with FHM
and shown to affect Cav2.1 Ca
2 channel gating
in functional studies.14 Thus, R583Q can be con-
sidered causative in our case.
ATP1A2. The five DNA variants in ATP1A2 in-
cluded four missense variants (E120A, E492K,
P786L, R908Q) and one nonsense mutation
(R834X). P786, R908, and R834 are completely
Figure 1 Pedigrees of sporadic hemiplegic migraine cases with a mutation in one of the familial hemiplegic
migraine genes (CACNA1A, ATP1A2, and SCN1A)
The following symbols are used to indicate the diagnosis: filled lower half  familial hemiplegic migraine; right upper
quadrant  migraine with aura; left upper quadrant  migraine without aura. Circle  female; square  male. Arrows
indicate probands. Individuals homozygous for the wild-type allele are indicated by WT; individuals heterozygous for a
DNA variant are indicated by the respective variant. Fam  family.
Table 2 DNA variants identified in pure SHM patients
Gene Amino acid change Nucleotide change Abnormality in functional test
CACNA1A R583Q nt2021GA Electrophysiologicconsequence
ATP1A2 E120A nt 463AC Partial cell survival
ATP1A2 E492K nt 1578GA Partial cell survival
ATP1A2 P786L nt 2604CT No cell survival
ATP1A2 R834X nt 2461CT No cell survival
ATP1A2 R908Q nt 2827GA No cell survival
SCN1A R1928G nt 5782CG No electrophysiologic consequence
SHM sporadic hemiplegic migraine.
Neurology 69 December 4, 2007 2173
conserved across multiple homologs and or-
thologs, whereas E120 and E492 are less well con-
served (figure E-1 on the Neurology® Web site at
www.neurology.org). The P786L mutation was
not present in the proband’s parents. False pater-
nity was excluded in this case. Thus, P786L repre-
sents a de novo mutation. E120A, E492K, and
R834X were all present in one or more relatives
who had no hemiplegic attacks, thus suggesting
incomplete penetrance. R908Q was not present in
the proband’s mother, but DNA from additional
family members was not available (figure 1).
Functional consequences of all five ATP1A2
variants were investigated using survival assays in
HeLa cells as previously reported for FHM2 muta-
tions.5,16 The survival assays test for the ability of
mutant protein to compensate for the loss of endog-
enous Na,K pump function, as achieved by ouabain
treatment (figure 2, C and D). Because of an altered
ouabain binding site, the transfected wild-type
(ATP1A2-WT) and mutant (ATP1A2-E120A,
ATP1A2-E492K,ATP1A2-P786L,ATP1A2-R834X,
ATP1A2-R908Q) Na,K-ATPase 2 subunits are
ouabain insensitive. Western blot analysis showed
that the constructs were expressed at comparable
levels (figure 2, A and B). In the survival assay, cells
expressing the wild-type construct survived ouabain
treatment. In contrast, ATP1A2 mutants gave no
(ATP1A2-P786L, ATP1A2-R834X, ATP1A2-
R908Q) or partial (ATP1A2-E120A [p  0.03],
ATP1A2-E492K [p  0.002]) cell survival, indicat-
ing a clear functional consequence for all mutants
(figure 2, C and D).
SCN1A. DNA variant R1928G in the SCN1A
gene was present in the index case and five addi-
tional family members, two of whom had non-
hemiplegic migraine. R1914G (which is
equivalent to SCN1A-R1928G) was introduced to
highly homologous human SCN5A (SCN5A-
R1914G) and functionally tested for its biophysi-
cal properties by patch clamp experiments in
transiently transfected human tsA201 cells.6 Cells
expressing the SCN5A-R1914G showed no signif-
icant difference in current density, steady state ac-
tivation, steady state inactivation, and recovery
from inactivation when compared with wild type
(table E-1). These results indicate that the variant
may be a DNA variant without a biologically sig-
nificant effect on Nav1.1 channel functioning.
DISCUSSION We screened 39 patients with
“pure” SHM without ataxia or other additional
neurologic features for mutations in the three
known FHM genes. In 7 patients, we found a se-
quence variant (table 2). None was found in 300
control chromosomes. Six of these showed obvi-
ous functional changes and can be considered
causal mutations. These results indicate that
genes for FHM are involved in at least a propor-
tion of patients with “pure” SHM. Our findings
have important pathogenetic, clinical, and diag-
nostic implications.
With our findings, a sensible approach to ge-
netic testing in SHM has become available to con-
firm the often difficult and clinically important
diagnosis of SHM.19 Because SHM patients with
de novo mutations may represent the founder of a
new family with highly disabling FHM, genetic
confirmation of the diagnosis may have conse-
quences for genetic counseling. When genetic test-
ing is considered in a patient with “pure” SHM,
the ATP1A2 gene should be screened first. We
found an ATP1A2 sequence variant in five of the
seven SHM cases with a confirmed sequence vari-
ant corresponding to 13% of the overall SHM
sample. This is a strikingly higher prevalence
compared with a previous study of the ATP1A2
gene that included patients with SHM but pro-
vided no specific clinical details.12
Our findings are in line with earlier smaller
studies showing that the yield of CACNA1A mu-
tations in SHM patients is low in the absence of
ataxia.20,21 In contrast, CACNA1A mutations
were found in 50% of SHM patients with associ-
ated cerebellar signs.7,9 The present study is the
Figure 2 Ouabain survival assay of novel
ATP1A2 DNA variants identified in
sporadic hemiplegic migraine
patients
(A and B) Western blot analysis of HeLa cells transfected
with wild-type (WT) or mutant ATP1A2 complementary DNA
(cDNA). (C and D) Ouabain sensitivity of cells transfected
with either wild-type or mutant ATP1A2 cDNA. Bars repre-
sent cell survival after 5 days of ouabain treatment (error
bars  SEM). * Partial survival is significantly lower than for
WT (p0.05). Mutants P786L, R834X, and R908Q gave no
survival. Ctrl control.
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first to evaluate the role of the recently identified
FHM3 gene6 in SHM. The likelihood of finding
SCN1A mutations in “pure” SHM, however,
seems very low.
Most ATP1A2 mutations in this study were
also found in asymptomatic relatives and in rela-
tives with nonhemiplegic migraine. They thus
showed reduced penetrance, as has also been no-
ticed for ATP1A2 mutations associated with
FHM2.22-24 This might explain why mutations in
the ATP1A2 gene are relatively common among
sporadic patients. In contrast, all SCN1A muta-
tions previously identified in FHM families
showed complete penetrance.6,17 This might relate
to the low yield of mutations in this gene in our
sample of sporadic cases.
Although we found FHM gene mutations in
18% of our patients with pure SHM, we did not
find mutations in the majority of our patients. It
is likely that when additional genes for FHM are
discovered, greater proportions of patients with
SHMwill prove to have mutations in FHM genes.
Until then, a diagnosis of SHM remains based on
the exclusion of other causes of recurrent hemipa-
resis, careful physical examination, detailed per-
sonal and family history, and regular follow-up.
In one patient (with ATP1A2 mutation R834X;
Family 5: figure 1), we had to change the initial
diagnosis of SHM to FHM when an additional
family member developed hemiplegic migraine
attacks several years after our initial investiga-
tion. A diagnosis of pure SHM is likely when
transient hemiparesis occurs in the course of a
typical attack of migraine with aura, when there
are no interictal abnormalities, and when “nor-
mal” attacks of migraine with or without aura are
present in first-degree relatives.25 Approximately
70% of pure SHM cases and 60% of the mutation
carriers had first-degree relatives with common
types of migraine.
Our findings provide genetic evidence that
FHM genes are also involved in SHM and thus
extend and reinforce the growing clinical, epide-
miologic, genetic, and pathophysiologic evidence
that FHM and SHM share neurobiological mech-
anisms.26 Moreover, because the majority of
hemiplegic migraine patients also have “normal”
attacks of migraine without hemiparesis, both
diseases can be considered extremes of the patho-
genetic migraine spectrum with shared common
pathways with “normal” migraine with and with-
out aura.26-29
We identified five sequence variants in
ATP1A2 (figure 1; Families 2 through 6). All con-
ferred reduced survival in cellular assays (figure 2)
and therefore are likely to be causative mutations.
P786L occurred de novo and could thus be the
founder of a new FHM family. R908Q was found
in a patient whose mother did not carry the muta-
tion. Because DNA from the father was not avail-
able, it could not be established whether the
mutation had occurred de novo. E120A and
E492K showed partially reduced survival (figure
2D). Both mutations were identified in other fam-
ily members who were unaffected or had non-
hemiplegic migraine with aura. The single
CACNA1Amutation (R583Q) we found was pre-
viously shown to affect Cav2.1 Ca
2 currents in
cellular models by changing channel gating.14 The
mutation was inherited from the mother, who has
attacks of nonhemiplegic migraine with aura. The
R1928G DNA variant that was identified in the
SCN1A gene did not reveal significant effects on
channel properties as investigated by electro-
physiologic recordings. Also, this variant poorly
segregates with the migraine phenotype. It was
present in five nonhemiplegic family members;
only one of them has migraine with aura, and an-
other has migraine without aura. R1928G may
therefore be a rare sequence variant without func-
tional consequences.
Screening of FHM genes in sporadic patients
with hemiplegic migraine may help to establish
the diagnosis, enable counseling, and prevent un-
necessary diagnostic and therapeutic trial with
potentially harmful drugs. Scanning of the FHM2
ATP1A2 gene seems to offer the highest likeli-
hood of success. Because FHM mutations were
also found in SHM and common types of mi-
graine with or without aura, our findings rein-
force the growing evidence that FHM, SHM,
basilar-type migraine, and “normal” migraine are
part of a disease spectrum with at least some
shared pathogenetic pathways. Unraveling these
pathways may help to identify novel migraine
prophylactic drugs.
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